{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=119",
    "query": {
      "intervention": "Protein Control",
      "page": 119
    },
    "page_size": 10
  },
  "pagination": {
    "page": 119,
    "page_size": 10,
    "total_count": 3500,
    "total_pages": 350,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=120&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=118&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T16:21:06.693Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04059666",
      "title": "Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gastrointestinal Microbiome"
      ],
      "interventions": [
        {
          "name": "Investigational",
          "type": "OTHER"
        },
        {
          "name": "Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Mead Johnson Nutrition",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Days",
        "maximum_age": "18 Days",
        "sex": "ALL",
        "summary": "7 Days to 18 Days"
      },
      "enrollment_count": 57,
      "start_date": "2019-03-05",
      "completion_date": "2022-02-02",
      "has_results": false,
      "last_update_posted_date": "2022-08-25",
      "last_synced_at": "2026-11-11T16:21:06.693Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Altamonte Springs, Florida • Owensboro, Kentucky + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Owensboro",
          "state": "Kentucky"
        },
        {
          "city": "Kingsport",
          "state": "Tennessee"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04059666"
    },
    {
      "nct_id": "NCT01010256",
      "title": "The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2009-11-01",
      "completion_date": "2019-10-03",
      "has_results": false,
      "last_update_posted_date": "2020-02-07",
      "last_synced_at": "2026-11-11T16:21:06.693Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01010256"
    },
    {
      "nct_id": "NCT03710122",
      "title": "Vancomycin for Primary Sclerosing Cholangitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis"
      ],
      "interventions": [
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Elizabeth Carey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "18 Years to 76 Years"
      },
      "enrollment_count": 102,
      "start_date": "2020-01-23",
      "completion_date": "2025-03-20",
      "has_results": true,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-11T16:21:06.693Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Jacksonville, Florida + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03710122"
    },
    {
      "nct_id": "NCT01804829",
      "title": "Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Infection",
        "Viruses",
        "Hepatocellular Carcinoma",
        "Hepatitis, Viral, Human",
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Civacir® 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biotest Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2013-06",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-11-11T16:21:06.693Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01804829"
    },
    {
      "nct_id": "NCT05013229",
      "title": "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "IcoSema",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 679,
      "start_date": "2021-11-30",
      "completion_date": "2023-11-14",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-11-11T16:21:06.693Z",
      "location_count": 66,
      "location_summary": "Guntersville, Alabama • Fresno, California • La Jolla, California + 59 more",
      "locations": [
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05013229"
    },
    {
      "nct_id": "NCT05846659",
      "title": "Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oligoprogressive"
      ],
      "interventions": [
        {
          "name": "IMSA101",
          "type": "DRUG"
        },
        {
          "name": "Immune checkpoint inhibitor",
          "type": "DRUG"
        },
        {
          "name": "PULSAR",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "ImmuneSensor Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2023-07-07",
      "completion_date": "2024-11-20",
      "has_results": true,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-11-11T16:21:06.693Z",
      "location_count": 14,
      "location_summary": "Irvine, California • Los Angeles, California • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05846659"
    },
    {
      "nct_id": "NCT07098988",
      "title": "Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non-Squamous Non-Small Cell Lung Cancer",
        "Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Visugromab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matching placebo for visugromab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab 200 mg Q3W",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pemetrexed 500 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin AUC 5",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CatalYm GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2025-08-01",
      "completion_date": "2031-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-11T16:21:06.693Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Derby, Connecticut + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Derby",
          "state": "Connecticut"
        },
        {
          "city": "Guilford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07098988"
    },
    {
      "nct_id": "NCT06019559",
      "title": "A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "K-757 120 mg BID and K-833 100 mg BID",
          "type": "DRUG"
        },
        {
          "name": "K-757 120 mg BID and matching placebo to K-833",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo to K-757 and matching placebo to K-833",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TriGemX Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 155,
      "start_date": "2023-09-15",
      "completion_date": "2024-02-19",
      "has_results": true,
      "last_update_posted_date": "2025-02-26",
      "last_synced_at": "2026-11-11T16:21:06.693Z",
      "location_count": 22,
      "location_summary": "San Diego, California • Stockbridge, Georgia • Topeka, Kansas + 19 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Hyattsville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06019559"
    },
    {
      "nct_id": "NCT02536170",
      "title": "Arginine Therapy for Sickle Cell Disease Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Vaso-occlusive Pain Episode"
      ],
      "interventions": [
        {
          "name": "L-arginine",
          "type": "DRUG"
        },
        {
          "name": "L-arginine Loading Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 108,
      "start_date": "2016-02",
      "completion_date": "2021-02-21",
      "has_results": true,
      "last_update_posted_date": "2023-09-06",
      "last_synced_at": "2026-11-11T16:21:06.693Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02536170"
    },
    {
      "nct_id": "NCT06635902",
      "title": "Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Vaso-occlusive Pain Episode"
      ],
      "interventions": [
        {
          "name": "L-citrulline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Suvankar Majumdar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "4 Years to 21 Years"
      },
      "enrollment_count": 99,
      "start_date": "2024-12-22",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-11T16:21:06.693Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06635902"
    }
  ]
}